Clinical Outcomes of Patient Subgroups in the TANGO II Study.

ABSTRACT:

Introduction

Meropenem-vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited applicability to daily medical practice as they often focus on indications such as urinary tract infections or skin and soft tissue infections, which generally have patients with fewer comorbid conditions that the typical patients who develops infection with CRE. The more useful studies are pathogen-focused trials which do not exclude the more complicated subjects with conditions such as renal failure, immunocompromised status, or exposure to prior antibiotic therapy.

Methods

The TANG

SUBMITTER: Bhowmick T 

PROVIDER: S-EPMC7872113 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature